In the positive control analysis, 14 of 18 antidiabetic drug targets were markedly associated with T2DM and/or random blood glucose, thereby passing the positive control analysis, while the targets ABCB11/LRP2, INS, KCNJ1, and ABCC11 were excluded, as they were not significantly associated with either a reduced risk of T2DM or a lowered random blood glucose (Figure 2A; Table S4). The gene discussed is LRP2; the disease is type 2 diabetes mellitus.